CalciMedica (CALC) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palatin Technologies (PTN) has outperformed CalciMedica (CALC) over the past year, losing 79.9% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | PTN |
|---|---|---|
| Share price | $1.26 | $4.58 |
| Market cap | $8.69M | $8.16M |
| 1-day change | +7.69% | -7.10% |
| YTD return | -96.18% | -70.22% |
| 1-year return | -92.34% | -79.93% |
| 5-year return | — | -99.35% |
| EPS (TTM) | $-4.41 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.83M |
| Net income (latest FY) | $-29.56M | $-8.38M |
| Operating margin | — | -98.17% |
| Net margin | — | -94.88% |
| 52-week high | $36.00 | $31.00 |
| 52-week low | $1.00 | $4.51 |
| Distance from 52-week high | -96.50% | -85.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3868.25% | +1068.12% |
| Average volume | 80.15K | 71.93K |
| Shares outstanding | 6.90M | 1.78M |
| Employees | 15 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed CALC by 12.4 percentage points over the past year.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CALC vs PTN FAQ
Which is bigger, CalciMedica or Palatin Technologies?
CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.16M for Palatin Technologies (PTN).
Which stock has performed better over the past year, CALC or PTN?
PTN returned -79.93% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are CalciMedica and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.